期刊文献+

人血管抑素AK(1—3)基因的克隆表达、纯化及活性鉴定

The Cloning expression, purification and activity of human angiostatin K (1-3) gene
原文传递
导出
摘要 目的克隆人AngiostatinK(1-3)基因,获得有活性的重组人血管抑素蛋白,为进一步开发应用奠定基础。方法以人新鲜肝脏组织为材料,通过RT—PCR得到人Angiostatin基因的AK(1—3)片段。构建重组质粒pET30a—Angiostatin,转化表达菌Rosetta(DE3),对转化子进行诱导表达,利用Ni—NTA亲和层析纯化目的产物,并验证其活性。结果获得了人Angiostatin基因AK(1-3)片段的正确序列,表达和纯化了人血管抑素蛋白,表达量占菌体总蛋白的30%,纯化后证明表达产物具有较高纯度(达到90%)。结论AngiostatinK(1-3)可在原核融合蛋白表达载体中表达,且得到有活性的目的蛋白。 Objective To clone the sequence of human Angiostatin cDNA and obtain the protein of recombinant angiostatin for further development. Methods Fresh human liver tissure was used for the extraction of total RNA and amplified the Angiostatin eDNA through RT-PCR method . After the recombinant plasmid pET30a- Angiostatin was constructed and confirmed, it was transduced into Rosetta (DE3). Then the transformation was used for fermentation and induced expression.The protein was identified by Western Blot and purified by Ni-NTA affinity chromatography. Results The sequence of human Augiostatin eDNA was identical with genebank. Angiostatin(K1-3) was expressed and purified. The target protein made up 30 % of tile total bacterial protein. The purity is above 90% . Conclusion Angiostatin K (1-3) can be reached using fusion vector pET30a. The product have the biological activity.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2009年第3期191-193,共3页 Chinese Journal of Experimental and Clinical Virology
关键词 血管生成抑制剂 包涵体 基因表达 印迹法 蛋白质 Angiogenesis inhibitors Inclusion bodies Gene expression Blotting Western
  • 相关文献

参考文献3

二级参考文献19

  • 1张庶民,祁自柏.基因工程表达蛋白包涵体的形成和纯化[J].微生物学免疫学进展,1995,23(1):52-54. 被引量:9
  • 2白东亭,许丽锋.重组大肠杆菌的包涵体[J].中国生物制品学杂志,1996,9(4):188-191. 被引量:16
  • 3Arnaiz-Villena A, Martinez-Laso J, Castro MJ et al . The evolution of the MHC-G gene does not support a functional role for the complete protein [J]. Immunol Rev,2001; 183:65-75.
  • 4Casro M J, Morales P, Rojo-Amigo R et al. Homozygous HLA-G *0105N healthy individuals indicate that membrane-associated HLA-G1molecule is not necessary for survival [J] .Tissue Antigens,2000;56(3):232-239.
  • 5Lila N, Amrein C, Guillemain R et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection [J]. Circulation,2002; 105(16): 1949-1954.
  • 6Paul P, Rouas-Freiss N, Khalil-Daher I et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance [J]. Proc Natl Acad Sci USA, 1998; 95:4510-4515.
  • 7Urosevic M, Trojan A, Dummer R. HLA-G and its KIR ligands in cancer-another enigma yet to be solved? [ J ]. J Pathol, 2002; 196 (3): 252-253.
  • 8Fournel S, Aguerre-Girr M, Huc X et al. Cutting edge: soluble HLA-G1triggers CD95/CD95 ligand-mediated apoptosis in activated CD8 + cells by interacting with CD8 [J] .J Immunol,2000; 164:6100-6104.
  • 9Carosella E D, Moreau P, Aractingi S et al. HLA-G:a shield against inflammatory aggression [J]. Trends in Immunology, 2001; 22(10): 553-555.
  • 10HarlowE LaneD 沈关心 龚非力译.抗体实验技术指南[M].北京:科学出版社,2002.265-266.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部